Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Study sponsor: Protagonist Therapeutics, Inc. · PTGX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-04-01Estimated
Enrollment · participants46Actual
Source updated2025-08-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.